SALUTENSIN-DEMI
LOE ApproachingNDAORALTABLET
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALUTENSIN-DEMI is an oral tablet small molecule approved in 1960 by Takeda. The specific indication and mechanism of action are not disclosed in available data, limiting characterization of its therapeutic positioning.
LOE Approaching
Product faces imminent loss of exclusivity with moderate competitive pressure (30); expect team consolidation and transition focus to generic defense or line extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings reflect a mature, declining-stage product with minimal hiring. Roles on this brand involve managing decline, optimizing remaining revenue, and preparing for generic transition rather than growth initiatives.
Brand ManagerProduct Manager
Worked on SALUTENSIN-DEMI at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.